Table 4. Multivariate analysis of prognostic factors with DFS and OS for breast cancer patients.
| Characteriscs | Disease free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| Patients (Relapse) | HR (95% CI)a | Log-rank p | Patients (Death) | HR (95% CI)a | Log-rank p | |
| Age | ||||||
| >40 | 693 (229) | 1.00 | 693 (151) | 1.00 | ||
| ≤40 | 276 (108) | 1.17 (0.81–1.67) | 0.404 | 276 (66) | 1.16 (0.74–1.81) | 0.512 |
| Tumor size | ||||||
| ≤2 cm | 385 (81) | 1.00 | 385 (53) | 1.00 | ||
| >2 cm | 584 (256) | 2.44 (1.90–3.14) | <0.01 | 584 (164) | 2.24 (1.65–3.06) | <0.01 |
| Lymph node involvement | ||||||
| No | 479 (104) | 1.00 | 479 (50) | 1.00 | ||
| Yes | 490 (233) | 2.61 (2.07–3.29) | <0.01 | 490 (167) | 3.81 (2.78–5.23) | <0.01 |
| Molecular subtype | ||||||
| Luminal type | 644 (191) | 1.00 | 644 (109) | 1.00 | ||
| HER-2 overexpression | 149 (65) | 1.78 (1.34–2.36) | <0.01 | 149 (46) | 2.16 (1.53–3.05) | <0.01 |
| TNBC | 176 (81) | 1.89 (1.45–2.45) | <0.01 | 176 (62) | 2.56 (1.87–3.49) | <0.01 |
| Adjuvant chemotherapy | ||||||
| Yes | 919 ( 325) | 1.00 | 919 (211) | 1.00 | ||
| No | 50 (12) | 1.46 (0.82–2.61) | 0.201 | 50 (6) | 2.12 (0.94–4.82) | 0.072 |
| rs1899663 G>T | ||||||
| GG | 628 (217) | 1.00 | 628 (137) | 1.00 | ||
| GT | 299 (102) | 0.97 (0.77–1.23) | 0.825 | 299 (69) | 1.06 (0.80–1.42) | 0.685 |
| TT | 42 (18) | 1.53 (0.94–2.48) | 0.086 | 42 (11) | 1.41 (0.76–2.61) | 0.277 |
| GT + TT | 341 (120) | 1.03 (0.82–1.29) | 0.796 | 341 (80) | 1.10 (0.83–1.45) | 0.502 |
| rs4759314 A>G | ||||||
| AA | 801 (275) | 1.00 | 801 (179) | 1.00 | ||
| GA | 157 (61) | 1.06 (0.80–1.40) | 0.669 | 157 (37) | 0.94 (0.66–1.34) | 0.734 |
| GG | 11 (1) | 0.24 (0.03–1.72) | 0.156 | 11 (1) | 0.43 (0.06–3.07) | 0.400 |
| GA + GG | 168 (62) | 1.01 (0.76–1.33) | 0.962 | 168 (38) | 0.91 (0.64–1.30) | 0.604 |
| rs7958904 G>C | ||||||
| GG | 489 (168) | 1.00 | 489 (106) | 1.00 | ||
| GC | 396 (136) | 0.96 (0.76–1.20) | 0.690 | 396 (89) | 0.99 (0.75–1.31) | 0.945 |
| CC | 84 (33) | 1.20 (0.82–1.74) | 0.348 | 84 (22) | 1.25 (0.79–1.98) | 0.339 |
| GC + CC | 480 (169) | 0.99 (0.80–1.23) | 0.959 | 480 (111) | 1.03 (0.79–1.34) | 0.811 |
aData were estimated by Cox regression analyses with adjustment for age, tumor size, lymph node status, ER,PR and Her-2 status where appropriate.